HWG Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

HWG Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,278	Closed	-$1.06M	–	56
2024 Q3	$1.06M	Buy	2,278 +2,269	+25,211%	+$1.09M	0.36%	38
2024 Q2	$4.22K	Buy	+9	New	+$3.91K	﹤0.01%	98
2023 Q4	$3.66K	Hold	9	–	–	﹤0.01%	107
2023 Q3	$3.13K	Hold	9	–	–	﹤0.01%	117
2023 Q2	$3.17K	Buy	+9	New	+$3.03K	﹤0.01%	124
2023 Q1	–	Sell	-349	Closed	-$101K	–	135
2022 Q4	$101K	Buy	349 +2	+0.6%	+$610	0.07%	52
2022 Q3	$100K	Buy	+347	New	+$99.8K	0.07%	43
2020 Q4	–	Sell	-3,469	Closed	-$796K	–	117
2020 Q3	$944K	Sell	3,469 -5,192	-60%	-$1.43M	0.84%	30
2020 Q2	$2.51M	Buy	+8,661	New	+$2.35M	2.01%	13
2019 Q2	–	Sell	-9	Closed	-$2K	–	147
2019 Q1	$2K	Sell	9 -3	-25%	-$554	﹤0.01%	91
2018 Q4	$2K	Buy	+12	New	+$2.08K	﹤0.01%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

HWG Holdings's VRTX Position: Q4 2024 in Review

HWG Holdings sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 2,278 shares — an estimated $1.06M sold.

HWG Holdings first reported a position in VRTX in Q4 2018 and held it in 11 quarters. The position peaked at $2.51M in Q2 2020. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

HWG Holdings reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
HWG Holdings sold 2,278 Vertex Pharmaceuticals shares in Q4 2024, an estimated $1.06M.
HWG Holdings first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 11 quarters.
HWG Holdings's Vertex Pharmaceuticals position peaked at $2.51M in Q2 2020.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on HWG Holdings's 13F filing for Q4 2024, filed 27 Feb 2025.